右美托咪定治疗缺血/再灌注损伤研究进展

背景 右美托咪定(dexmedetomidine,Dex)是新一代α2受体激动药,广泛应用于临床麻醉、重症监护及术后镇静,对部分器官的缺血性损伤有保护作用. 目的 总结Dex治疗缺血/再灌注损伤(ischemia/reperfusion injury,I/RI)的研究进展,为临床及科研提供参考. 内容 Dex在一些重要的器官和组织(小肠、心脏、肾、肺和肝)I/RI中表现出保护作用,机制与其调节基因表达、离子通道激活、递质释放、炎症过程以及细胞凋亡和坏死有关. 趋向 Dex有望成为治疗I/RI的一个选择.

Research progress of dexmedetomidine in the treatment of ischemia/reperfusion injury

Background Dexmedetomidine (Dex) is a selective and potent a2 adrenergic receptor agonist,which has been widely used in clinical anesthesia,intensive care unit,postoperative sedation,and organ protection during ischemia/reperfusion injury (I/RI).Objective To summarize the research progress of Dex in the treatment of I/RI.Content Dex has been demonstrated to protect I/RI in a variety of important tissues and organs,which includes intestine,heart,kidney,lung,brain and liver.These protective effects of Dex might relate to the modulation of gene expression,channel activation,transmitter release,inflammatory processes,apoptosis,and necrosis.Trend Dex may offer a new therapeutic approach for the treatment of I/RI with the expandation of its biological activity spectrum.